Emtricitabine/tenofovir disoproxil fumarate 200mg/300 mg tablets (Mylan Labs Ltd†), HA417

Steps taken following Prequalification of [HA417 trade name]¹

Changes	WHOPAR parts affected	Accepted on
Change in dimensions of container closure system with deletion of void filler and change of desiccant for HDPE container pack size 30's	3, 4	12 October 2010
Change in the name of the supplier and manufacturer of the FPP	3, 4, 5	18 October 2011
Change in the pack size of the FPP	3, 4, 5	25 June 2016
Change in the name and/or address of the supplier of the FPP	3, 4, 5	01 March 2017
Addition of a primary packing type for the FPP	3, 4, 5	24 August 2017
Addition of FPP manufacturing and testing site	3	14 December 2017
General update of the WHOPAR to reflect the current WHOPAR structure, product specifics, WHO guidelines and state of scientific knowledge	2, 3, 4	June 2020

¹ Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.

[†] Formerly Matrix Laboratories Limited.